Inrebic, Krysbita, and Brukinsa pass the Health Insurance Review and Assessment Service (HIRA) evaluation.
Meanwhile, Xofluza and Ozempic conditionally passed the evaluation for acceptance at a lower reimbursement rate.
Inrebic capsule, Krysbita injection, and Brukinsa capsule have overcome the HIRA evaluation stage, where the appropriateness of their coverage was recognized. From now on, these drugs will move on to the health insurance negotiation stage to ultimately challenge their reimbursement.
On April 9, 2023, the HIRA announced that it had evaluated the appropriateness of medical treatments, including the listed drugs.
First, the Krysbita injection (burosumab) from Kyowa Kirin for FGF23-related hypophosphatemic rickets and osteomalacia treatment was deemed appropriate for reimbursement. It is reportedly excellent for pediatric rickets symptoms, and the National Health Insurance Corporation is considering shortening the negotiation period for drug prices.
In addition, Inrebic capsules (fedratinib hydrochloride) from Korea BMs Pharmaceutical, which treat primary myelofibrosis in adult patients previously treated with ruxolitinib, secondary myelofibrosis following polycythemia vera, or myelofibrosis related to essential thrombocythemia or symptomatic splenomegaly, also received reimbursement appropriateness recognition.
Bruckinza capsules (zanubrutinib), a new drug introduced by the Chinese pharmaceutical company BeiGene Korea, were judged by HIRA to be appropriate for reimbursement for Waldenstrom's macroglobulinemia (WM) among three indications.
Two drugs, Jaledip capsules (zaleplon) for short-term treatment of adult insomnia from Bukwang Pharmaceutical and Ozempic pre-filled pens (semaglutide) as an adjunct to diet and exercise therapy for adults with insufficiently controlled type 2 diabetes from Novo Nordisk, conditionally passed the evaluation for acceptance at a lower reimbursement rate.
Meanwhile, JW Pharmaceutical's Hemlibra, a treatment for hemophilia, is said to have passed a plan to expand reimbursement to non-antibody patients during the HIRA evaluation.